- Previous Close
12,050.00 - Open
11,912.00 - Bid 11,780.00 x --
- Ask 11,784.00 x --
- Day's Range
11,712.00 - 11,948.04 - 52 Week Range
9,461.00 - 13,388.00 - Volume
368,614 - Avg. Volume
1,699,699 - Market Cap (intraday)
182.663B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
37.29 - EPS (TTM)
3.16 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield 2.34 (1.94%)
- Ex-Dividend Date Aug 8, 2024
- 1y Target Est
133.44
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com89,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AZN.L
View MorePerformance Overview: AZN.L
Trailing total returns as of 9/13/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZN.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZN.L
View MoreValuation Measures
Market Cap
186.81B
Enterprise Value
207.10B
Trailing P/E
38.13
Forward P/E
16.78
PEG Ratio (5yr expected)
0.88
Price/Sales (ttm)
4.99
Price/Book (mrq)
6.16
Enterprise Value/Revenue
5.50
Enterprise Value/EBITDA
19.17
Financial Highlights
Profitability and Income Statement
Profit Margin
13.11%
Return on Assets (ttm)
7.68%
Return on Equity (ttm)
16.74%
Revenue (ttm)
49.13B
Net Income Avi to Common (ttm)
6.44B
Diluted EPS (ttm)
3.16
Balance Sheet and Cash Flow
Total Cash (mrq)
7.08B
Total Debt/Equity (mrq)
84.97%
Levered Free Cash Flow (ttm)
9.82B
Research Analysis: AZN.L
View MoreCompany Insights: AZN.L
AZN.L does not have Company Insights